Investing.com — PTC Therapeutics, Inc. (NASDAQ: PTCT)，一家市值为44.9亿美元的生物制药公司，在美国医学遗传学与基因组学学院年度临床遗传学会议上展示了其第三阶段APHENITY试验及后续研究的新发现，突显了使用sepiapterin治疗苯丙酮尿症 (PKU)的进展。根据 InvestingPro ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics ...

(PTCT), Thursday announced new data of the Phase 3 APHENITY trial and subsequent open-label extension study, evaluating the potential meaningful benefits of sepiapterin treatment in ...

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth with upcoming FDA reviews.

PTC Therapeutics (PTCT) shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 ...

JPMorgan analyst Eric Joseph raised the firm’s price target on PTC Therapeutics (PTCT) to $78 from $72 and keeps an Overweight rating on the ...

The data suggest that a significant majority of PKU patients could benefit from dietary liberalization while maintaining blood phenylalanine (Phe) control with sepiapterin treatment. The APHENITY ...

(NASDAQ: PTCT), a biopharmaceutical company with a market capitalization of $4.49 billion, has presented new findings from its Phase 3 APHENITY trial and subsequent studies at the American College of ...